Department of Otolaryngology Head and Neck Surgery, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Unit of Otolaryngology Head and Neck Surgery, IRCCS Policlinico San Martino Hospital, Genoa, Italy.
Acta Otorhinolaryngol Ital. 2023 Apr;43(Suppl. 1):S111-S122. doi: 10.14639/0392-100X-suppl.1-43-2023-14.
Recurrent respiratory papillomatosis (RRP) is a benign, rare disease caused by Human Papilloma Virus (HPV) that can be divided into juvenile and adult forms. The course of the disease is variable, but is usually more aggressive in the juvenile form. The standard surgical treatment is represented by CO laser resection, although photoangiolytic lasers represent a valid alternative. Adjuvant therapies have been proposed for disease control in case of frequent surgical resections or spreading into the lower airways. In recent years, the development of immunotherapy led to the use of bevacizumab either intratumorally or intravenously, but the most promising therapeutic development is represented by HPV vaccination. This paper aims to present a narrative review of the literature and the experience of three different University Centres in the treatment of RRP.
A retrospective analysis of the clinical charts of all patients affected by laryngeal papillomatosis and treated in three different University Centres between 2002 and 2022 was performed. The following parameters were collected: sex, age at first evaluation, sites of larynx involved, HPV type, type of first surgical treatment, presence and number of recurrences, surgical treatment of recurrences, adjuvant therapies, side effects and status at last follow-up.
Seventy-eight patients were available for evaluation. Of these, 88% had adult onset RRP (Ao-RRP) and 12% juvenile onset RRP (Jo-RRP). The glottis was the most frequently involved subsite; all patients were submitted to surgical resection with CO laser under general anaesthesia. Recurrences appeared in 79% of the patients, the patients who did not recur were all adults. The mean number of recurrences was 9 (range 1-110). Recurrences were more frequent in children (M = 20; range 2-110) than adults (M = 5; range 1-21). Thirty-two (52%) of the 62 patients who recurred were re-treated with CO laser under general anaesthesia, while office-based treatment with a photoangiolytic laser was preferred in the remaining 30 (48%) patients. Adjuvant treatments were applied in 26 patients. The analysis of the course of the disease showed that in the 9 patients with Jo-RRP, 6 (67%) were free of lesions at the last follow-up, while the other 3 (33%) had papillomas. Of the 69 patients with Ao-RRP, 53 (77%) were alive and free of disease at the last visit, 14 (21%) were alive with disease, 1 (1%) was lost at follow-up and 1 (1%) died for other disease. Severe side effects were not observed except for 2 patients, who developed posterior glottic stenosis.
Our results confirmed the literature review. RRP is a potentially aggressive disease, especially in juvenile onset. Surgical resection is still first-line treatment, but in case of multiple recurrences the use of adjuvant therapies must be taken into consideration.
复发性呼吸道乳头瘤病(RRP)是一种由人乳头瘤病毒(HPV)引起的良性、罕见疾病,可分为青少年型和成人型。疾病的病程是多变的,但在青少年型中通常更为激进。标准的手术治疗方法是 CO2 激光切除术,尽管光动力疗法激光是一种有效的替代方法。在需要频繁手术切除或病变扩散到下呼吸道的情况下,已经提出了辅助治疗来控制疾病。近年来,免疫疗法的发展导致了贝伐单抗的应用,无论是瘤内注射还是静脉内注射,但最有前途的治疗进展是 HPV 疫苗接种。本文旨在对文献进行综述,并介绍三个不同大学中心在治疗 RRP 方面的经验。
对 2002 年至 2022 年间在三个不同大学中心接受治疗的所有喉乳头状瘤病患者的临床图表进行回顾性分析。收集了以下参数:性别、首次评估时的年龄、受累喉部部位、HPV 类型、首次手术治疗类型、有无复发、复发病例的手术治疗、辅助治疗、副作用和末次随访时的状况。
共有 78 例患者可进行评估。其中,88%为成人发病 RRP(Ao-RRP),12%为青少年发病 RRP(Jo-RRP)。声门是最常受累的部位;所有患者均在全身麻醉下接受 CO2 激光切除术。79%的患者出现复发,未复发的患者均为成年人。复发的平均次数为 9 次(范围 1-110 次)。儿童的复发次数(M=20;范围 2-110)多于成年人(M=5;范围 1-21)。62 例复发患者中,有 32 例(52%)再次接受全身麻醉下 CO2 激光治疗,而 30 例(48%)患者选择在办公室接受光动力疗法激光治疗。26 例患者接受了辅助治疗。对疾病病程的分析表明,在 9 例青少年发病 RRP 患者中,6 例(67%)末次随访时无病变,而其余 3 例(33%)有乳头瘤。在 69 例成人发病 RRP 患者中,53 例(77%)末次随访时存活且无疾病,14 例(21%)存活但有疾病,1 例(1%)失访,1 例(1%)因其他疾病死亡。除 2 例患者发生后声门狭窄外,未观察到严重副作用。
我们的结果证实了文献综述。RRP 是一种潜在侵袭性疾病,尤其是在青少年发病时。手术切除仍然是一线治疗方法,但在多次复发的情况下,必须考虑使用辅助治疗。